Intravitreal bevacizumab (Avastin) treatment of macular edema in branch retinal vein occlusion
10.3969/j.issn.1672-5123.2009.03.003
- VernacularTitle:玻璃体腔注射Bevacizumab治疗视网膜分支静脉阻塞性黄斑水肿
- Author:
Bo, QIN
;
Shen-Wen, LIU
;
Jian, ZENG
;
Xun-Qing, GU
- Publication Type:Journal Article
- Keywords:
bevacizumab(Avastin);
macular edema;
branch retinal vein occlusion
- From:
International Eye Science
2009;09(3):414-416
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To report the safty and efficiency of intravitreal injection of bevacizumab (Avastin) in patients with macular edema (ME) due to branch retinal vein occlusion (BRVO).METHODS: A consecutive series of patients with ME due to BRVO who were treated with intravitreal bevacizumab injection (2.5g/0.1L) were retrospectively studied. Patients underwent complete ophthalmoscopic examination, including Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and/or flurescence angiographic testing at baseline and follow-up visits.RESULTS: There were 32 eyes of 32 consecutive patients who received at least one intravitreal bevacizumab injections (range from 1 to 3). The mean length of follow-up was 4.7 (range from 3 to 8) months. The mean visual acuity improved from 20/200- at baseline to 20/100- at 1 month and 20/100+ at 3 months and last follow-up (P＜0.01). The mean central 1mm macular thickness was 483μm at baseline and decreased to 275, 314,and 301μm at 1 month,3 months, and last follow-up (P＜0.01)respectively.No adverse side effects were observed following injections in any eyes.CONCLUSION: Intravitreal bevacizumab (Avastin) showed a marked decrease in ME secondary to BRVO, improvement in visual acuity and lack of adverse side effects.
